Fibrosis stage alone does not fully capture ongoing fibrogenic activity or the biological mechanisms driving fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).
- Effective patient stratification may therefore require complementary assessment of fibrogenic activity using non-invasive tests (NITs), such as PRO-C3, AST¹, FAST score¹, LiverPRO², and biological drivers of fibrosis progression, captured through tissue-derived molecular and cellular features.
- Building on the “hot vs cold” fibrosis framework³, we combined AI-derived macrophage quantification with PRO-C3 to define four fibrosis phenotypes—hot-progressive, hot-regressive, cold-progressive, and cold-regressive—and characterized their proteomic, metabolomic, and transcriptomic signatures.
AASLD
Takeda